Julie Wolf

Effects of Smoking on the Pharmacokinetics of Erlotinib

Marta Hamilton, Julie Wolf, Jason Rusk et al. · Clinical Cancer Research · 2006 · 311 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys

Daniel W. Drolet, J. Arly Nelson, Christopher E. Tucker et al. · Pharmaceutical Research · 2000 · 204 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Andrew Hughes, Mary O’Brien, W. Jeffrey Petty et al. · Journal of Clinical Oncology · 2009 · 142 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Paul Frohna, Jianfeng Lu, Steve Eppler et al. · The Journal of Clinical Pharmacology · 2006 · 111 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.

Frank C. Richardson, Geoffrey D. Young, Regina Sennello et al. · PubMed · 2012 · 54 citations

Medicine, Oncology, Pharmacology +17